Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy
Open Access
- 12 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9), e45063
- https://doi.org/10.1371/journal.pone.0045063
Abstract
Calcitriol antiproliferative effects include inhibition of the oncogenic ether-à-go-go-1 potassium channel (Eag1) expression, which is necessary for cell cycle progression and tumorigenesis. Astemizole, a new promising antineoplastic drug, targets Eag1 by blocking ion currents. Herein, we characterized the interaction between calcitriol and astemizole as well as their conjoint antiproliferative action in SUM-229PE, T-47D and primary tumor-derived breast cancer cells. Molecular markers were studied by immunocytochemistry, Western blot and real time PCR. Inhibitory concentrations were determined by dose-response curves and metabolic activity assays. At clinically achievable drug concentrations, synergistic antiproliferative interaction was observed between calcitriol and astemizole, as calculated by combination index analysis (CI P20 values were 1.82±2.41 nM and 1.62±0.75 µM; for calcitriol (in estrogen receptor negative cells) and astemizole, respectively. Real time PCR showed that both drugs alone downregulated, while simultaneous treatment further reduced Ki-67 and Eag1 gene expression (P<0.05). Astemizole inhibited basal and calcitriol-induced CYP24A1 and CYP3A4 mRNA expression (cytochromes involved in calcitriol and astemizole degradation) in breast and hepatoma cancer cells, respectively, while upregulated vitamin D receptor (VDR) expression. Astemizole synergized calcitriol antiproliferative effects by downregulating CYP24A1, upregulating VDR and targeting Eag1. This study provides insight into the molecular mechanisms involved in astemizole-calcitriol combined antineoplastic effect, offering scientific support to test both compounds in combination in further preclinical and clinical studies of neoplasms expressing VDR and Eag1. VDR-negative tumors might also be sensitized to calcitriol antineoplastic effects by the use of astemizole. Herein we suggest a novel combined adjuvant therapy for the management of VDR/Eag1-expressing breast cancer tumors. Since astemizole improves calcitriol bioavailability and activity, decreased calcitriol dosing is advised for conjoint administration.This publication has 55 references indexed in Scilit:
- Functional KV10.1 Channels Localize to the Inner Nuclear MembranePLOS ONE, 2011
- 20-Hydroxyvitamin D2is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cellsAmerican Journal of Physiology-Cell Physiology, 2011
- Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesionsBMC Cancer, 2010
- CYP24A1 Inhibition Enhances the Antitumor Activity of CalcitriolEndocrinology, 2010
- Calcitriol inhibits Ether-à go-go potassium channel expression and cell proliferation in human breast cancer cellsExperimental Cell Research, 2010
- Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and TherapyThe Cancer Journal, 2010
- Eag1 as a cancer targetEmerging Therapeutic Targets, 2008
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007
- Vitamin D and prevention of breast cancerActa Pharmacologica Sinica, 2007
- Ether à go-go potassium channels and cancerCancer Letters, 2006